<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1624">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351490</url>
  </required_header>
  <id_info>
    <org_study_id>2020_30</org_study_id>
    <secondary_id>2020-A00873-36</secondary_id>
    <nct_id>NCT04351490</nct_id>
  </id_info>
  <brief_title>Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19</brief_title>
  <acronym>ZnD3-CoVici</acronym>
  <official_title>Impact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mortality from Covid-19 increases with age, reaching 14.8% from the age of 80. The severity
      of the infection is linked to the acute respiratory distress syndrome (ARDS) which requires
      intensive care. ARDS is the consequence of the reactional inflammatory storm that damages the
      lungs.

      Aged subjects are particularly prone to zinc and vitamin D deficiency. These two
      micronutrients are able to modulate the immune response by reducing the inflammatory storm.

      The hypothesis is that supplementation with zinc and vitamin D would reduce the inflammatory
      reaction which worsens ARDS and leads to the death of subjects infected with Covid-19.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate in asymptomatic subjects at inclusion</measure>
    <time_frame>Two months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate in symptomatic subjects at inclusion</measure>
    <time_frame>Two months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate in overall subjects</measure>
    <time_frame>Two months after inclusion</time_frame>
    <description>symptomatic subjects and asymptomatic subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of Covid-19 infection in asymptomatic subjects at inclusion</measure>
    <time_frame>Within two months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3140</enrollment>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Group supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group usual treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc gluconate</intervention_name>
    <description>Zinc gluconate capsule 15 mg x 2 per day during 2 months</description>
    <arm_group_label>Group supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>25-OH cholecalciferol</intervention_name>
    <description>25-OH cholecalciferol drinkable solution 10 drops (2000 IU) per day during 2 months</description>
    <arm_group_label>Group supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Institutionalized

        Exclusion Criteria:

          -  Life expectancy &lt; 1 month independently of Covid-19 infection (overall subjects)

          -  Known hypercalcemia

          -  History of renal lithiasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David SEGUY, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David SEGUY, MD,PhD</last_name>
    <phone>0320444850</phone>
    <phone_ext>+33</phone_ext>
    <email>david.seguy@chru-lille.fr</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Survival</keyword>
  <keyword>Covid-19</keyword>
  <keyword>Aged subjects</keyword>
  <keyword>Zinc</keyword>
  <keyword>25-OH cholecalciferol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

